ITP showdown: daily pill vs IV infusion in major new trial

NCT ID NCT07051915

Not yet recruiting Disease control Sponsor: Ostfold Hospital Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial will compare two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. About 220 adults who didn't respond to steroids will be randomly assigned to take avatrombopag (a daily pill that boosts platelet production) or rituximab (an IV infusion that targets immune cells). The main goal is to see which treatment leads to more stable platelet counts over 28 weeks, with follow-up on quality of life and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Avatrombopag (daily pill) or Rituximab (IV infusion)
What this could lead to: If successful, this could show which second-line treatment works better for ITP patients who didn't respond to steroids, potentially improving platelet counts and quality of life.
What could go wrong: This is a phase 3 trial, but it's not yet recruiting. Results may not apply to all ITP patients, and both drugs have side effects like infection risk (rituximab) or liver issues (avatrombopag).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOCYTOPENIA PURPURA

More trials for these conditions

Other studies related to the condition(s) this trial covers.